Cisplatin induced arrhythmia; electrolyte imbalance or disturbance of the SA node?

Rabbab Oun, Edward Rowan

Research output: Contribution to journalArticle

13 Citations (Scopus)
33 Downloads (Pure)

Abstract

Since its approval in 1979 cisplatin has become one of the most extensively used chemotherapeutics in the clinic and although cell resistance and toxicity hinder its efficacy it continues to be a gold standard regimen. Cisplatin's side effects primarily include nephrotoxicity, gastrointestinal toxicity, neurotoxicity and ototoxicity. Cardiotoxicity is generally not defined as a side effect of cisplatin. However, over the past decade there has been a surge in the amount of clinical cases reporting a vast array of cardio-toxic events occurring during or shortly after cisplatin infusion, these range from angina to cardiac ischemia and chronic heart failure. This review intends to discuss the clinical cardiac manifestations of cisplatin specifically tachycardia and bradycardia which can be lethal and the possible mechanisms of action.

Original languageEnglish
Number of pages4
JournalEuropean Journal of Pharmacology
Early online date6 Jun 2017
DOIs
Publication statusE-pub ahead of print - 6 Jun 2017

Fingerprint

Cisplatin
Electrolytes
Cardiac Arrhythmias
Poisons
Bradycardia
Tachycardia
Ischemia
Heart Failure

Keywords

  • cisplatin
  • cardiotoxicity
  • arrhythmia
  • platinum
  • chemotherapy

Cite this

@article{7e562dccc61544828bb60d40d9e505a1,
title = "Cisplatin induced arrhythmia; electrolyte imbalance or disturbance of the SA node?",
abstract = "Since its approval in 1979 cisplatin has become one of the most extensively used chemotherapeutics in the clinic and although cell resistance and toxicity hinder its efficacy it continues to be a gold standard regimen. Cisplatin's side effects primarily include nephrotoxicity, gastrointestinal toxicity, neurotoxicity and ototoxicity. Cardiotoxicity is generally not defined as a side effect of cisplatin. However, over the past decade there has been a surge in the amount of clinical cases reporting a vast array of cardio-toxic events occurring during or shortly after cisplatin infusion, these range from angina to cardiac ischemia and chronic heart failure. This review intends to discuss the clinical cardiac manifestations of cisplatin specifically tachycardia and bradycardia which can be lethal and the possible mechanisms of action.",
keywords = "cisplatin, cardiotoxicity, arrhythmia, platinum, chemotherapy",
author = "Rabbab Oun and Edward Rowan",
note = "Crown Copyright {\circledC} 2017. Published by Elsevier B.V. All rights reserved.",
year = "2017",
month = "6",
day = "6",
doi = "10.1016/j.ejphar.2017.05.063",
language = "English",
journal = "European Journal of Pharmacology",
issn = "0014-2999",

}

TY - JOUR

T1 - Cisplatin induced arrhythmia; electrolyte imbalance or disturbance of the SA node?

AU - Oun, Rabbab

AU - Rowan, Edward

N1 - Crown Copyright © 2017. Published by Elsevier B.V. All rights reserved.

PY - 2017/6/6

Y1 - 2017/6/6

N2 - Since its approval in 1979 cisplatin has become one of the most extensively used chemotherapeutics in the clinic and although cell resistance and toxicity hinder its efficacy it continues to be a gold standard regimen. Cisplatin's side effects primarily include nephrotoxicity, gastrointestinal toxicity, neurotoxicity and ototoxicity. Cardiotoxicity is generally not defined as a side effect of cisplatin. However, over the past decade there has been a surge in the amount of clinical cases reporting a vast array of cardio-toxic events occurring during or shortly after cisplatin infusion, these range from angina to cardiac ischemia and chronic heart failure. This review intends to discuss the clinical cardiac manifestations of cisplatin specifically tachycardia and bradycardia which can be lethal and the possible mechanisms of action.

AB - Since its approval in 1979 cisplatin has become one of the most extensively used chemotherapeutics in the clinic and although cell resistance and toxicity hinder its efficacy it continues to be a gold standard regimen. Cisplatin's side effects primarily include nephrotoxicity, gastrointestinal toxicity, neurotoxicity and ototoxicity. Cardiotoxicity is generally not defined as a side effect of cisplatin. However, over the past decade there has been a surge in the amount of clinical cases reporting a vast array of cardio-toxic events occurring during or shortly after cisplatin infusion, these range from angina to cardiac ischemia and chronic heart failure. This review intends to discuss the clinical cardiac manifestations of cisplatin specifically tachycardia and bradycardia which can be lethal and the possible mechanisms of action.

KW - cisplatin

KW - cardiotoxicity

KW - arrhythmia

KW - platinum

KW - chemotherapy

U2 - 10.1016/j.ejphar.2017.05.063

DO - 10.1016/j.ejphar.2017.05.063

M3 - Article

C2 - 28599874

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -